{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:40Z","timestamp":1792700020641,"version":"4.5.0"},"reference-count":189,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cyclic nucleotides (cAMP, cGMP) play a major role in normal and pathologic signaling. Beyond receptors, cyclic nucleotide phosphodiesterases; (PDEs) rapidly convert the cyclic nucleotide in its respective 5\u2032-nucleotide to control intracellular cAMP and\/or cGMP levels to maintain a normal physiological state. However, in many pathologies, dysregulations of various PDEs (PDE1-PDE11) contribute mainly to organs and tissue failures related to uncontrolled phosphorylation cascade. Among these, PDE4 represents the greatest family, since it is constituted by 4 genes with multiple variants differently distributed at tissue, cellular and subcellular levels, allowing different fine-tuned regulations. Since the 1980s, pharmaceutical companies have developed PDE4 inhibitors (PDE4-I) to overcome cardiovascular diseases. Since, they have encountered many undesired problems, (emesis), they focused their research on other PDEs. Today, increases in the knowledge of complex PDE4 regulations in various tissues and pathologies, and the evolution in drug design, resulted in a renewal of PDE4-I development. The present review describes the recent PDE4-I development targeting cardiovascular diseases, obesity, diabetes, ulcerative colitis, and Crohn\u2019s disease, malignancies, fatty liver disease, osteoporosis, depression, as well as COVID-19. Today, the direct therapeutic approach of PDE4 is extended by developing allosteric inhibitors and protein\/protein interactions allowing to act on the PDE interactome.<\/jats:p>","DOI":"10.3390\/ijms231810616","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:06:52Z","timestamp":1663103212000},"page":"10616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-1331","authenticated-orcid":false,"given":"Claire","family":"Lugnier","sequence":"first","affiliation":[{"name":"Section de Structures Biologiques, Pharmacologie et Enzymologie, CNRS\/Unistra, CRBS, UR 3072, CEDEX, 67084 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_2","first-page":"1335","article-title":"Les phosphodiest\u00e9rases des nucl\u00e9otides cycliques","volume":"12","author":"Mulller","year":"1993","journal-title":"Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/pr.116.013078","article-title":"International Union of Basic and Clinical Pharmacology. CI. Structures and small molecule modulators of mammalian adenylyl cyclases","volume":"69","author":"Dessauer","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pozdniakova, S., and Ladilov, Y. (2018). Functional significance of the adcy10-Dependent intracellular cAMP Compartments. J. Cardiovasc. Dev. Dis., 5.","DOI":"10.3390\/jcdd5020029"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-642-17969-3_2","article-title":"Phosphodiesterase inhibitors: Factors that influence potency, selectivity, and action","volume":"204","author":"Francis","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: Important signaling modulators and therapeutic targets","volume":"21","author":"Ahmad","year":"2015","journal-title":"Oral Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lugnier, C., Meyer, A., Charloux, A., Andr\u00e8s, E., Geny, B., and Talha, S. (2019). The Endocrine function of the heart: Physiology and involvements of natriuretic peptides and cyclic nucleotide phosphodiesterases in heart failure. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101746"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107475","DOI":"10.1016\/j.pharmthera.2020.107475","article-title":"Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?","volume":"208","author":"Lugnier","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fertig, B.A., and Baillie, G.S. (2018). PDE4-Mediated cAMP Signalling. J. Cardiovasc. Dev. Dis., 5.","DOI":"10.3390\/jcdd5010008"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0006-291X(83)91091-4","article-title":"Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity","volume":"113","author":"Lugnier","year":"1983","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0006-2952(86)90333-3","article-title":"Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta","volume":"35","author":"Lugnier","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(86)90210-4","article-title":"Stereospecific binding of the antidepressant rolipram to brain protein structures","volume":"127","author":"Schneider","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/jm00127a009","article-title":"Inhibition of cyclic adenosine-3\u2032,5\u2032-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues","volume":"32","author":"Marivet","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1476-5381.1991.tb09790.x","article-title":"Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by \u2018type IV\u2019-selective PDE inhibitors","volume":"103","author":"Dent","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","first-page":"2678","article-title":"Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase","volume":"10","author":"Livi","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0021-9258(17)42355-6","article-title":"Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites","volume":"269","author":"Monaco","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: Phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1054-3589(08)60128-3","article-title":"The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions","volume":"44","author":"Houslay","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"30338","DOI":"10.1074\/jbc.M312687200","article-title":"The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases","volume":"279","author":"Richter","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_22","first-page":"1","article-title":"Cyclic nucleotide phosphodiesterases: Relating structure and function","volume":"65","author":"Francis","year":"2001","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bjp.0703636","article-title":"Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases","volume":"131","author":"Baillie","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Beavo, J.A., Francis, S.H., and Houslay, M. (2006). Cellular functions of PDE4 enzymes. Cyclic Nucleotide Phosphodiesterases in Health and Disease, CRC Press.","DOI":"10.1201\/9781420020847.ch1"},{"key":"ref_25","first-page":"674","article-title":"The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity","volume":"273","author":"Barnette","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","first-page":"1396","article-title":"Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site","volume":"273","author":"Barnette","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_27","first-page":"891","article-title":"Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding","volume":"50","author":"Jacobitz","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0898-6568(96)00173-8","article-title":"Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases","volume":"9","author":"Souness","year":"1997","journal-title":"Cell Signal."},{"key":"ref_29","first-page":"817","article-title":"Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: Consequences for the utero-relaxant effect of PDE4-selective inhibitors","volume":"292","author":"Tanguy","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00213-006-0369-4","article-title":"Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats","volume":"186","author":"Zhang","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast\u2013A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_32","first-page":"105","article-title":"Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis","volume":"8","author":"Fala","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","article-title":"Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice","volume":"43","author":"Zhang","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2174\/138161210790963760","article-title":"Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs","volume":"16","author":"Keravis","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/embor.2013.4","article-title":"\u00df1-adrenergic receptor antagonists signal via PDE4 translocation","volume":"14","author":"Richter","year":"2013","journal-title":"EMBO Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1021\/acs.biochem.8b00336","article-title":"Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors","volume":"57","author":"Feng","year":"2018","journal-title":"Biochemistry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1517\/13543784.4.11.1081","article-title":"Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases","volume":"4","author":"Stoclet","year":"1995","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1476-5381.1991.tb12457.x","article-title":"Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors","volume":"104","author":"Komas","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"ref_40","first-page":"141","article-title":"Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation","volume":"14","author":"Lugnier","year":"1993","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1476-5381.1994.tb17009.x","article-title":"Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO\/cyclic GMP pathway","volume":"113","author":"Eckly","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","unstructured":"Savineau, J.P. (2007). Cyclic nucleotide phosphodiesterase (PDE) superfamily and smooth muscle signaling. New Frontiers in Smooth Muscle Biology and Physiology, Transworld Research, Network."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0006-2952(90)90650-A","article-title":"Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells","volume":"39","author":"Lugnier","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000025738","article-title":"Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: Differential regulation in cobblestone and spindle phenotypes","volume":"37","author":"Keravis","year":"2000","journal-title":"J. Vasc. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH03-12-0768","article-title":"Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4","volume":"92","author":"Favot","year":"2004","journal-title":"Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Beavo, J.A., Francis, S.H., and Houslay, M. (2006). Role of PDEs in vascular health and disease: Endothelial PDEs and angiogenesis. Cyclic Nucleotide Phosphodiesterases in Health and Disease, CRC Press.","DOI":"10.1201\/9781420020847.ch1"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0922-4106(95)90030-6","article-title":"Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells","volume":"290","author":"Kessler","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","first-page":"181","article-title":"Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4","volume":"174","author":"Suttorp","year":"1996","journal-title":"Lung"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33614","DOI":"10.1074\/jbc.M110.140004","article-title":"Cyclic AMP phosphodiesterase 4D (PDE4D) tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability","volume":"285","author":"Rampersad","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1111\/bph.12853","article-title":"Alteration of vascular reactivity in heart failure: Role of phosphodiesterases 3 and 4","volume":"171","author":"Hubert","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Varona, S., Puertas, L., Gal\u00e1n, M., Orriols, M., Ca\u00f1es, L., Aguil\u00f3, S., Camacho, M., Sirvent, M., Andr\u00e9s, V., and Mart\u00ednez-Gonz\u00e1lez, J. (2021). Rolipram prevents the formation of abdominal aortic aneurysm (AAA) in Mice: PDE4B as a target in AAA. Antioxidants, 10.","DOI":"10.3390\/antiox10030460"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"H751","DOI":"10.1152\/ajpheart.00673.2018","article-title":"Phosphodiesterase-4 inhibition reduces ECLS-induced vascular permeability and improves microcirculation in a rodent model of extracorporeal resuscitation","volume":"316","author":"Wollborn","year":"2019","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"ref_53","first-page":"363","article-title":"Cyclic AMP and contractile activity in heart","volume":"8","author":"Tsien","year":"1977","journal-title":"Adv. Cycl. Nucleotide Res."},{"key":"ref_54","first-page":"506","article-title":"Isolation and characterization of bovine cardiac muscle cGMP- inhibited phosphodiesterase: A receptor for new cardiotonic drugs","volume":"29","author":"Harrison","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00005344-198908000-00005","article-title":"Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues","volume":"14","author":"Komas","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00005344-199003000-00015","article-title":"Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria","volume":"15","author":"Muller","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-7-67","article-title":"Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure","volume":"7","author":"Lanfear","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1016\/0006-2952(88)90400-5","article-title":"Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors","volume":"37","author":"Prigent","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.1988.tb33348.x","article-title":"Cyclic nucleotides and calcium regulation in heart and smooth muscle cells","volume":"522","author":"Stoclet","year":"1988","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_60","first-page":"H654","article-title":"Cyclic nucleotide phosphodiesterases from frog atrial fibers: Isolation and drug sensitivities","volume":"262","author":"Lugnier","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0922-4106(92)90028-T","article-title":"Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles","volume":"225","author":"Muller","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/00005344-199011000-00016","article-title":"Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction","volume":"16","author":"Muller","year":"1990","journal-title":"Cardiovasc. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bph.12168","article-title":"PDE4 in the human heart\u2013major player or little helper?","volume":"168","author":"Eschenhagen","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_64","first-page":"1142","article-title":"Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions","volume":"265","author":"Lugnier","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0304-4165(99)00145-2","article-title":"Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei","volume":"1472","author":"Lugnier","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/cvr\/cvy110","article-title":"PDE4 and mAKAP\u03b2 are nodal organizers of \u03b22-ARs nuclear PKA signalling in cardiac myocytes","volume":"114","author":"Bedioune","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1074\/jbc.M006546200","article-title":"Myomegalin is a novel protein of the Golgi\/centrosome that interacts with a cyclic nucleotide phosphodiesterase","volume":"276","author":"Verde","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2005.07.030","article-title":"Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias","volume":"123","author":"Lehnart","year":"2005","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCRESAHA.109.197947","article-title":"Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals","volume":"105","author":"Richter","year":"2009","journal-title":"Circ. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00395-010-0138-8","article-title":"Conserved expression and functions of PDE4 in rodent and human heart","volume":"106","author":"Richter","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mokni, W., Keravis, T., Etienne-Selloum, N., Walter, A., Kane, M.O., Schini-Kerth, V.B., and Lugnier, C. (2010). Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014227"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.111.250464","article-title":"Phosphodiesterase 4D (PDE4D) regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current","volume":"109","author":"Beca","year":"2011","journal-title":"Circ. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1172\/JCI44747","article-title":"Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice","volume":"121","author":"Leroy","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cellsig.2015.02.003","article-title":"UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00395-020-0810-6","article-title":"Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects","volume":"115","author":"Lindner","year":"2020","journal-title":"Basic Res. Cardiol."},{"key":"ref_76","first-page":"113","article-title":"The pathogenesis of obesity from a genomic and systems biology perspective","volume":"87","author":"Levian","year":"2014","journal-title":"Yale J. Biol. Med."},{"key":"ref_77","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2015\u20132016","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Briefs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tcb.2012.07.004","article-title":"Resveratrol as a calorie restriction mimetic: Therapeutic implications","volume":"22","author":"Chung","year":"2012","journal-title":"Trends Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/nutd.2011.9","article-title":"Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity","volume":"1","author":"Omar","year":"2011","journal-title":"Nutr. Diabetes"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1124\/mol.112.084145","article-title":"PDE3 and PDE4 isozyme-selective inhibitors are both required for synergistic activation of brown adipose tissue","volume":"83","author":"Kraynik","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: A pilot randomized study","volume":"8","author":"Jensterle","year":"2015","journal-title":"J. Ovarian Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/en.2009-0108","article-title":"Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B","volume":"150","author":"Zhang","year":"2008","journal-title":"Endocrinology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Al Amrani, A., Abdel Karim, M., and Al Zoghaibi, M. (2018). PRDM16 Gene Polymorphism is associated with obesity and blood lipids profiles in Saudi population. J. Clin. Med., 7.","DOI":"10.3390\/jcm7060141"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbrc.2018.10.180","article-title":"Compound D159687, a phosphodiesterase 4D inhibitor, induces weight and fat mass loss in aged mice without changing lean mass, physical and cognitive function. Biochem","volume":"506","author":"Muo","year":"2018","journal-title":"Biophys. Res. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"662451","DOI":"10.3389\/fendo.2021.662451","article-title":"Roflumilast suppresses adipogenic differentiation via AMPK mediated pathway","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1210\/en.2017-03273","article-title":"\u03b2-Cell Autophagy in Diabetes Pathogenesis","volume":"159","author":"Marasco","year":"2018","journal-title":"Endocrinology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10408363.2017.1299684","article-title":"Evaluation of glycated albumin (GA) and GA\/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review","volume":"54","author":"Yazdanpanah","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4615-1321-6_32","article-title":"Cyclic nucleotide phosphodiesterase families in intracellular signaling and diabetes","volume":"498","author":"Lugnier","year":"2001","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1006\/bbrc.1995.2858","article-title":"Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: Contributions of types III and IV to the modulation of insulin secretion","volume":"217","author":"Parker","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bcp.2008.07.025","article-title":"Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832\/13) cells and rat islets","volume":"76","author":"Waddleton","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_92","first-page":"5084","article-title":"Role of phosphodiesterases in the shaping of sub-plasma-membrane cAMP oscillations and pulsatile insulin secretion","volume":"125","author":"Tian","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/dom.12839","article-title":"The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism","volume":"19","author":"Kahles","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cts.12436","article-title":"Pharmacokinetic\/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction","volume":"10","author":"Plock","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"110185","DOI":"10.1016\/j.cellsig.2021.110185","article-title":"Phosphodiesterase 4 inhibitors in diabetic nephropathy","volume":"90","author":"Ookawara","year":"2022","journal-title":"Cell Signal."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/DMSO.S182953","article-title":"Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight\/obesity involve age-associated fat mass loss\u2013results of an exploratory study","volume":"12","author":"Muo","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn\u2019s disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.39.5.684","article-title":"Increased production of tumour necrosis factor-\u03b1, interleukin-1\u03b2, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn\u2019s disease","volume":"39","author":"Reimund","year":"1996","journal-title":"Gut"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/gut.40.4.475","article-title":"In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease","volume":"40","author":"Reimund","year":"1997","journal-title":"Gut"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00018-016-2446-0","article-title":"Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions","volume":"74","author":"Tetsi","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_101","first-page":"G3716","article-title":"First characterisation of cyclic nucleotide phosphodiesterase isoforms in normal human mucosa and inflamed mucosa from Crohn\u2019s disease patients","volume":"116","author":"Arondel","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0891-5849(00)00471-8","article-title":"OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability","volume":"30","author":"Banan","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"ref_103","first-page":"502","article-title":"Tetomilast","volume":"8","year":"2005","journal-title":"IDrugs"},{"key":"ref_104","first-page":"22","article-title":"Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice","volume":"292","author":"Hartmann","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1124\/jpet.105.090837","article-title":"Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis","volume":"316","author":"Videla","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Spadaccini, M., D\u2019Alessio, S., Peyrin-Biroulet, L., and Danese, S. (2017). PDE4 Inhibition and Inflammatory Bowel Disease: A novel therapeutic avenue. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061276"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Picchianti-Diamanti, A., Spinelli, F.R., Rosado, M.M., Conti, F., and Lagan\u00e0, B. (2021). Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052638"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e00442","DOI":"10.14309\/ctg.0000000000000442","article-title":"Combined endoscopic and radiologic healing is associated with a better prognosis than endoscopic healing only in patients with Crohn\u2019s disease receiving anti-TNF therapy","volume":"13","author":"Oh","year":"2022","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/GME.0000000000001263","article-title":"Advances in osteoporosis from 1970 to 2018","volume":"25","author":"Gallagher","year":"2018","journal-title":"Menopause"},{"key":"ref_110","first-page":"131","article-title":"Prevalencia de osteoporosis y osteopenia en pacientes laboralmente activos","volume":"32","year":"2018","journal-title":"Acta Ortop. Mex."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11657-018-0540-7","article-title":"Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: A systematic review and meta-analysis","volume":"13","author":"Zamani","year":"2018","journal-title":"Arch. Osteoporos."},{"key":"ref_112","first-page":"R106","article-title":"Phosphodiesterase isoenzymes in different tissues and the selective inhibition by denbufylline","volume":"339","author":"Lugnier","year":"1989","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1476-5381.1989.tb12029.x","article-title":"The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site","volume":"97","author":"Nicholson","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0006-2952(97)00211-6","article-title":"Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4","volume":"54","author":"Miyamoto","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1254\/jjp.79.477","article-title":"Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models","volume":"79","author":"Waki","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S8756-3282(00)00395-1","article-title":"Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice","volume":"27","author":"Kinoshita","year":"2000","journal-title":"Bone"},{"key":"ref_117","unstructured":"Boudjema, N. (2002). Inhibiteurs de phosphodiestrase type 4: Int\u00e9r\u00eat potentiel dans le traitement de l\u2019ost\u00e9oporose. [Master\u2019s Thesis, Faculty of Pharmacy]."},{"key":"ref_118","first-page":"119","article-title":"Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats","volume":"7","author":"Yao","year":"2007","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_119","first-page":"305","article-title":"Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation","volume":"10","author":"Pekkinen","year":"2005","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcp.2004.09.012","article-title":"Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells","volume":"69","author":"Pekkinen","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"ref_121","first-page":"201","article-title":"PDE4 inhibitor suppresses PGE2-induced osteoclast formation via COX-2-mediated p27(KIP1) expression in RAW264.7 cells","volume":"66","author":"Chen","year":"2011","journal-title":"Pharmazie"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bonr.2018.02.005","article-title":"Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats","volume":"8","author":"Stern","year":"2018","journal-title":"Bone Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"174015","DOI":"10.1016\/j.ejphar.2021.174015","article-title":"Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs","volume":"899","author":"Porwal","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.V92.7.2484","article-title":"Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia","volume":"92","author":"Kim","year":"1998","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02737806","article-title":"Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts","volume":"28","author":"Marko","year":"1998","journal-title":"Cell. Biochem. Biophys."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00001813-200306000-00009","article-title":"Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition","volume":"14","author":"Narita","year":"2003","journal-title":"Anticancer. Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1160\/TH03-02-0084","article-title":"VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors","volume":"90","author":"Favot","year":"2003","journal-title":"Thromb. Haemost."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1160\/TH14-05-0454","article-title":"Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition","volume":"113","author":"Abusnina","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2015.302","article-title":"A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma","volume":"30","author":"Suhasini","year":"2016","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"42026","DOI":"10.1074\/jbc.M406530200","article-title":"Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways","volume":"279","author":"Parrella","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_132","unstructured":"Keravis, T., Justiniano, H., Guillemin, M.C., de Th\u00e9, H., Rochette-Egly, C., and Lugnier, C. (2011.Poster, January 22\u201325). cAMP-PDE activity, PDE4 activity and PDE4D protein expression are increased in RA-resistant NB4-R2 cells. Proceedings of the EMBO Retinoids 2011: Mechanisms, Biology and pathology of Signaling by Retinoic acid and Retinoic acid Receptors, Strasbourg, France."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Pleiman, J.K., Irving, A.A., Wang, Z., Toraason, E., Clipson, L., Dove, W.F., Dustin, A., Deming, D.A., and Newton, M.A. (2018). The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007611"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/0008-5472.CAN-09-3769","article-title":"Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of Neurofibromatosis-1","volume":"70","author":"Warrington","year":"2010","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"112341","DOI":"10.18632\/oncotarget.22866","article-title":"F.; Zhang. Y.; Wu, H.; Wu, F. Roflumilast restores cAMP\/PKA\/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/CS20180519","article-title":"Creating a potential diagnostic for prostate cancer risk stratification (InformMDx\u2122) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7)","volume":"133","author":"Henderson","year":"2019","journal-title":"Clin. Sci."},{"key":"ref_137","first-page":"3589","article-title":"Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT\/mTOR\/Myc signaling pathway","volume":"17","author":"Kim","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7145198","DOI":"10.1155\/2019\/7145198","article-title":"PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway","volume":"2019","author":"Kong","year":"2019","journal-title":"Anal. Cell. Pathol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3892\/ijmm.2016.2763","article-title":"The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK\/CCL2 pathway in bone cancer pain","volume":"38","author":"Guo","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejmech.2018.03.046","article-title":"Inhibitors of phosphodiesterase as cancer therapeutics","volume":"150","author":"Peng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1038\/s41388-020-1258-8","article-title":"PDE4 subtypes in cancer","volume":"39","author":"Zervoudakis","year":"2020","journal-title":"Oncogene"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2019.00563","article-title":"Targeting myeloid-derived cells: New frontiers in the treatment of non-alcoholic and alcoholic liver disease","volume":"10","author":"Vonghia","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/jpet.113.204933","article-title":"Rolipram attenuates bile duct ligation-induced liver injury in rats: A potential pathogenic role of PDE4","volume":"347","author":"Gobejishvili","year":"2013","journal-title":"J. Pharmacol. Exp. Pathol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/path.4760","article-title":"Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis","volume":"240","author":"Avila","year":"2016","journal-title":"J. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/hep.30761","article-title":"Phosphodiesterase 4 inhibition as a therapeutic target for alcoholic liver disease: From bedside to bench","volume":"70","author":"Rodriguez","year":"2019","journal-title":"Hepatology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00213-011-2290-8","article-title":"Inhibition of phosphodiesterase-4 decreases ethanol intake in mice","volume":"218","author":"Hu","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"106004","DOI":"10.1016\/j.phrs.2021.106004","article-title":"Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-beta1 pathway: Therapeutic role of roflumilast","volume":"175","author":"Tao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2147\/DDDT.S355796","article-title":"Novel liposomal rolipram formulation for clinical application to reduce emesis","volume":"16","author":"Gobejishvili","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0028-3908(83)90239-3","article-title":"Potential antidepressant activity of rolipram and other selective cyclic adenosine 3\u2032,5\u2032-monophosphate phosphodiesterase inhibitors","volume":"22","author":"Wachtel","year":"1983","journal-title":"Neuropharmacology"},{"key":"ref_155","first-page":"1168","article-title":"Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate","volume":"264","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e15020","DOI":"10.1073\/pnas.95.25.15020","article-title":"Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory","volume":"95","author":"Barad","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","first-page":"587","article-title":"Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme","volume":"27","author":"Zhang","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd2058","article-title":"Phosphodiesterases in the CNS: Targets for drug development","volume":"5","author":"Menniti","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuropharm.2011.03.020","article-title":"L Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B- knockout (PDE4B\u2212\/\u2212) mice","volume":"61","author":"Rutten","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1073\/pnas.1822113116","article-title":"Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases","volume":"116","author":"Omar","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Campbell, S.L., van Groen, T., Kadish, I., Smoot, L.H.M., and Bolger, G.B. (2017). Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus. BMC Neurosci., 18.","DOI":"10.1186\/s12868-017-0396-6"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"11332","DOI":"10.1038\/srep11332","article-title":"Phosphodiesterase-4D knock-down in the prefrontal cortex alleviates chronic unpredictable stress-induced depressive-like behaviors and memory deficits in mice","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","article-title":"The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses","volume":"303","author":"Vanmierlo","year":"2016","journal-title":"Behav. Brain. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-319-58811-7_4","article-title":"The PDE4 cAMP-specific phosphodiesterases: Targets for drugs with antidepressant and memory-enhancing action","volume":"17","author":"Bolger","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1042\/BST20190763","article-title":"Understanding PDE4\u2032s function in Alzheimer\u2019s disease; a target for novel therapeutic approaches","volume":"47","author":"Tibbo","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e7171","DOI":"10.7717\/peerj.7171","article-title":"Identification of diagnostic markers for major depressive disorder by cross-validation of data from whole blood samples","volume":"7","author":"Wang","year":"2019","journal-title":"PeerJ"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","article-title":"The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer\u2019s Disease: A Preclinical Study in APP\/PS1 Transgenic Mice","volume":"23","author":"Wang","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_168","first-page":"971","article-title":"Phosphodiesterase type 4 inhibition in CNS diseases","volume":"40","author":"Blokland","year":"2019","journal-title":"TIPS"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"114431","DOI":"10.1016\/j.bcp.2021.114431","article-title":"PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking","volume":"185","author":"Lugnier","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/00002030-199510000-00004","article-title":"Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication","volume":"9","author":"Angel","year":"1995","journal-title":"AIDS"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/JVI.72.6.4712-4720.1998","article-title":"Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: Involvement of NF-\u03baB and NFAT","volume":"72","author":"Navarro","year":"1998","journal-title":"J. Virol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.4049\/jimmunol.165.4.1755","article-title":"Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4","volume":"165","author":"Sun","year":"2000","journal-title":"J. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Mata, M., Martinez, I., Melero, J.A., Tenor, H., and Cortijo, J. (2013). Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069670"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1465-9921-14-127","article-title":"Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle","volume":"14","author":"James","year":"2013","journal-title":"Respir. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jix547","article-title":"Regulatory T Cells Contribute to HIV-1 Reservoir persistence in CD4+ T cells through cyclic adenosine monophosphate\u2013dependent mechanisms in humanized mice in vivo","volume":"216","author":"Li","year":"2017","journal-title":"J. Inf. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS Coronavirus-Induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"154282","DOI":"10.1016\/j.metabol.2020.154282","article-title":"Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19","volume":"109","author":"Dalamaga","year":"2020","journal-title":"Metabolism"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"129868","DOI":"10.1016\/j.molstruc.2020.129868","article-title":"Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: Their sonochemical synthesis and in silico\/in vitro assessment","volume":"1230","author":"Chemboli","year":"2021","journal-title":"J. Mol. Struct."},{"key":"ref_179","first-page":"335","article-title":"Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond","volume":"22","author":"Bridgewood","year":"2020","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"101978","DOI":"10.1016\/j.pupt.2020.101978","article-title":"Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19","volume":"66","author":"Ranju","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"797390","DOI":"10.3389\/fimmu.2021.797390","article-title":"The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs","volume":"12","author":"Nguyen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: A concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101342","DOI":"10.1016\/j.redox.2019.101342","article-title":"Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2\/HO-1 pathway","volume":"28","author":"Xu","year":"2020","journal-title":"Redox Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.coph.2011.09.012","article-title":"PDE inhibitors: A new approach to treat metabolic syndrome?","volume":"11","author":"Lugnier","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cellsig.2015.10.005","article-title":"Protein\u2013protein interactions of PDE4 family members\u2013Functions, interactions and therapeutic value","volume":"28","author":"Klussmann","year":"2016","journal-title":"Cell Signal."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/BCJ20160849","article-title":"Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilized by multiple interaction partners","volume":"474","author":"Houslay","year":"2017","journal-title":"Biochem. J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: Inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Drug Discov."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Vi\u00f1a, D., Seoane, N., Vasquez, E.C., and Campos-Toimil, M. (2021). cAMP compartmentalization in cerebrovascular endothelial cells: New therapeutic opportunities in Alzheimer\u2019s disease. Cells, 10.","DOI":"10.3390\/cells10081951"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Schick, M.A., and Schlegel, N. (2022). Clinical implication of phosphodiesterase-4-inhibition. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031209"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:30:22Z","timestamp":1760142622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":189,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231810616"],"URL":"https:\/\/doi.org\/10.3390\/ijms231810616","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}